Toll-Like Receptor (<it>TLR</it>) and Nucleosome-binding Oligomerization Domain (<it>NOD</it>) gene polymorphisms and endometrial cancer risk
<p>Abstract</p> <p>Background</p> <p>Endometrial cancer is the most common gynaecological malignancy in women of developed countries. Many risk factors implicated in endometrial cancer trigger inflammatory events; therefore, alterations in immune response may predispose...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-07-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/10/382 |
| _version_ | 1811278545276633088 |
|---|---|
| author | McEvoy Mark Symonds Ian Otton Geoffrey Proietto Anthony Ashton Katie A Attia John Scott Rodney J |
| author_facet | McEvoy Mark Symonds Ian Otton Geoffrey Proietto Anthony Ashton Katie A Attia John Scott Rodney J |
| author_sort | McEvoy Mark |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Endometrial cancer is the most common gynaecological malignancy in women of developed countries. Many risk factors implicated in endometrial cancer trigger inflammatory events; therefore, alterations in immune response may predispose an individual to disease. Toll-like receptors (<it>TLRs</it>) and nucleosome-binding oligomerization domain (<it>NOD</it>) genes are integral to the recognition of pathogens and are highly polymorphic. For these reasons, the aim of the study was to assess the frequency of polymorphic variants in <it>TLR </it>and <it>NOD </it>genes in an Australian endometrial cancer population.</p> <p>Methods</p> <p>Ten polymorphisms were genotyped in 191 endometrial cancer cases and 291 controls using real-time PCR: <it>NOD1 </it>(rs2075822, rs2907749, rs2907748), <it>NOD2 </it>(rs5743260, rs2066844, rs2066845), <it>TLR2 </it>(rs5743708), <it>TLR4 </it>(rs4986790) and <it>TLR9 </it>(rs5743836, rs187084).</p> <p>Results</p> <p>Haplotype analysis revealed that the combination of the variant alleles of the two <it>TLR9 </it>polymorphisms, rs5743836 and rs187084, were protective for endometrial cancer risk: OR 0.11, 95% CI (0.03-0.44), p = 0.002. This result remained highly significant after adjustment for endometrial cancer risk factors and Bonferroni correction for multiple testing. There were no other associations observed for the other polymorphisms in <it>TLR2</it>, <it>TLR4</it>, <it>NOD1 </it>and <it>NOD2</it>.</p> <p>Conclusions</p> <p>The variant 'C' allele of rs5743836 causes greater <it>TLR9 </it>transcriptional activity compared to the 'T' allele, therefore, higher <it>TLR9 </it>activity may be related to efficient removal of microbial pathogens within the endometrium. Clearly, the association of these <it>TLR9 </it>polymorphisms and endometrial cancer risk must be further examined in an independent population. The results point towards the importance of examining immune response in endometrial tumourigenesis to understand new pathways that may be implicated in disease.</p> |
| first_indexed | 2024-04-13T00:36:30Z |
| format | Article |
| id | doaj.art-5672b3e89d984ee8b204c9dd9d2c7a13 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-13T00:36:30Z |
| publishDate | 2010-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-5672b3e89d984ee8b204c9dd9d2c7a132022-12-22T03:10:18ZengBMCBMC Cancer1471-24072010-07-0110138210.1186/1471-2407-10-382Toll-Like Receptor (<it>TLR</it>) and Nucleosome-binding Oligomerization Domain (<it>NOD</it>) gene polymorphisms and endometrial cancer riskMcEvoy MarkSymonds IanOtton GeoffreyProietto AnthonyAshton Katie AAttia JohnScott Rodney J<p>Abstract</p> <p>Background</p> <p>Endometrial cancer is the most common gynaecological malignancy in women of developed countries. Many risk factors implicated in endometrial cancer trigger inflammatory events; therefore, alterations in immune response may predispose an individual to disease. Toll-like receptors (<it>TLRs</it>) and nucleosome-binding oligomerization domain (<it>NOD</it>) genes are integral to the recognition of pathogens and are highly polymorphic. For these reasons, the aim of the study was to assess the frequency of polymorphic variants in <it>TLR </it>and <it>NOD </it>genes in an Australian endometrial cancer population.</p> <p>Methods</p> <p>Ten polymorphisms were genotyped in 191 endometrial cancer cases and 291 controls using real-time PCR: <it>NOD1 </it>(rs2075822, rs2907749, rs2907748), <it>NOD2 </it>(rs5743260, rs2066844, rs2066845), <it>TLR2 </it>(rs5743708), <it>TLR4 </it>(rs4986790) and <it>TLR9 </it>(rs5743836, rs187084).</p> <p>Results</p> <p>Haplotype analysis revealed that the combination of the variant alleles of the two <it>TLR9 </it>polymorphisms, rs5743836 and rs187084, were protective for endometrial cancer risk: OR 0.11, 95% CI (0.03-0.44), p = 0.002. This result remained highly significant after adjustment for endometrial cancer risk factors and Bonferroni correction for multiple testing. There were no other associations observed for the other polymorphisms in <it>TLR2</it>, <it>TLR4</it>, <it>NOD1 </it>and <it>NOD2</it>.</p> <p>Conclusions</p> <p>The variant 'C' allele of rs5743836 causes greater <it>TLR9 </it>transcriptional activity compared to the 'T' allele, therefore, higher <it>TLR9 </it>activity may be related to efficient removal of microbial pathogens within the endometrium. Clearly, the association of these <it>TLR9 </it>polymorphisms and endometrial cancer risk must be further examined in an independent population. The results point towards the importance of examining immune response in endometrial tumourigenesis to understand new pathways that may be implicated in disease.</p>http://www.biomedcentral.com/1471-2407/10/382 |
| spellingShingle | McEvoy Mark Symonds Ian Otton Geoffrey Proietto Anthony Ashton Katie A Attia John Scott Rodney J Toll-Like Receptor (<it>TLR</it>) and Nucleosome-binding Oligomerization Domain (<it>NOD</it>) gene polymorphisms and endometrial cancer risk BMC Cancer |
| title | Toll-Like Receptor (<it>TLR</it>) and Nucleosome-binding Oligomerization Domain (<it>NOD</it>) gene polymorphisms and endometrial cancer risk |
| title_full | Toll-Like Receptor (<it>TLR</it>) and Nucleosome-binding Oligomerization Domain (<it>NOD</it>) gene polymorphisms and endometrial cancer risk |
| title_fullStr | Toll-Like Receptor (<it>TLR</it>) and Nucleosome-binding Oligomerization Domain (<it>NOD</it>) gene polymorphisms and endometrial cancer risk |
| title_full_unstemmed | Toll-Like Receptor (<it>TLR</it>) and Nucleosome-binding Oligomerization Domain (<it>NOD</it>) gene polymorphisms and endometrial cancer risk |
| title_short | Toll-Like Receptor (<it>TLR</it>) and Nucleosome-binding Oligomerization Domain (<it>NOD</it>) gene polymorphisms and endometrial cancer risk |
| title_sort | toll like receptor it tlr it and nucleosome binding oligomerization domain it nod it gene polymorphisms and endometrial cancer risk |
| url | http://www.biomedcentral.com/1471-2407/10/382 |
| work_keys_str_mv | AT mcevoymark tolllikereceptorittlritandnucleosomebindingoligomerizationdomainitnoditgenepolymorphismsandendometrialcancerrisk AT symondsian tolllikereceptorittlritandnucleosomebindingoligomerizationdomainitnoditgenepolymorphismsandendometrialcancerrisk AT ottongeoffrey tolllikereceptorittlritandnucleosomebindingoligomerizationdomainitnoditgenepolymorphismsandendometrialcancerrisk AT proiettoanthony tolllikereceptorittlritandnucleosomebindingoligomerizationdomainitnoditgenepolymorphismsandendometrialcancerrisk AT ashtonkatiea tolllikereceptorittlritandnucleosomebindingoligomerizationdomainitnoditgenepolymorphismsandendometrialcancerrisk AT attiajohn tolllikereceptorittlritandnucleosomebindingoligomerizationdomainitnoditgenepolymorphismsandendometrialcancerrisk AT scottrodneyj tolllikereceptorittlritandnucleosomebindingoligomerizationdomainitnoditgenepolymorphismsandendometrialcancerrisk |